FluoroPharma Medical, Inc. (FPMI) Joins Major Players in PET Market
The use of PET scans (positron emission tomography) for identifying and evaluating cancer is well-known. Most of the millions of PET procedures currently performed in the U.S. every year relate to cancer diagnosis. But developers are now hot on the trail of other applications for this one-of-a-kind technology that has the potential for letting doctors and researchers see even the most minute biological processes, events happening at the cellular and molecular level, to spot disease processes long before they manifest themselves in traditional ways. Today researchers at FluoroPharma Medical, a developer of imaging agents used in conjunction with PET scanning,…